sofosbuvir/velpatasvir (SOF/VEL)

FDA approved for HIV/HCV co-infection
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

One tablet once daily with or without food. Pellets for pediatric use now available. Treatment is usually 12 weeks, but ribavirin may be added or treatment may be extended to 24 weeks for certain patients.

Each tablet used for adults contains 400 mg of sofosbuvir and 100 mg of velpatasvir. New oral pellet formulas approved in June (200 mg SOF/50 mg VEL or 150 mg SOF/37.5 mg VEL) now allow dosing in children age 3 and older (as opposed to age 6 and older previously), based on weight. (See Briefly, page 6.)

The brand name is dispensed in a bottle; the authorized generic is dispensed in a blister pack. The authorized generic was created to help lower cost and has identical ingredients as the brand name.

Take your missed dose as soon as possible unless it is less than 12 hours until your next dose. Do not double up on your next dose.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Epclusa, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could worsen or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation on page 37 for more information and consult your medical provider.

Epclusa dosing

Body weight

Dosing of Epclusa

Epclusa daily dose

More than 66 pounds (30 kg)

One 400 mg/100 mg tablet once daily

400 mg/100 mg per day

37.5 to 66 pounds (17–30 kg)

One 200 mg/50 mg tablet once daily

200 mg/50 mg per day


brand: Gilead Sciences; authorized generic: Asegua Therapeutics LLC


brand (400/100 mg and 250/50 mg tablets): $29,904 / month;
authorized generic (400/100 mg tablets only): $9,600 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information